SG-pembrolizumab posts 11.8-month PFS versus 7.7 months, misses significance
AI Summary- SG plus pembrolizumab failed to significantly improve PFS over pembrolizumab alone.
- Median PFS was 11.8 months versus 7.7 months; median OS was 21.5 versus 22.8 months.
- EVOKE-03/KEYNOTE-D46 enrolled 620 untreated patients with PD-L1 TPS of at least 50%.